THIS YEAR'S ASCO HOT TOPIC: PD-(L)1 AFTER TIGIT SINGLE RESISTANCE OR WILL LEAD THE FUTURE

Wen'sMay 14, 2020, 2020 ASCO release summary, also due to the impact of the new coronavirus outbreak, following the 2020 AACR, this year's ANNUAL ASCO annual meeting is also held onlineMuch progress deserves attention, in the author's opinion, TIGIT single anti-tiragolumab phase 2 clinical data is very worthy of attention!2011, the approval of Epiwood single anti-marketing opened the era of tumor immunity, the drug became the first approved tumor immuno-checkpoint drugs,2014, Navuliyu monoantigen and Paboli zhu monoantigen approved to market to accelerate tumor therapy into the era of tumor immunity, PD-(L)1 antibody has become a powerful driving force to drive the rapid growth of the tumor market, such antibody drugs to a variety of solid tumor treatment breakthrough progress, change the treatment of a variety of cancerHowever, the clinical benefits of PD-(L)1 antibodies to cancer patients are still limited and innovative therapies still need to be exploredIn addition to APC submitting antigen information, T-cell activation still has an important second signal, the co-pandery and co-stimuloric moleculesIn normal physiological conditions, co-inhibitory and co-stimulor molecules regulate immune balance in both directions, the tumor environment, the body is in an immunosuppressive state, tumor cells immune escapeTherefore, by regulating the immune checkpoint pathway, it is possible to relieve the immunosuppressive state, it is worth noting: 1.co-inhibitory immuno-checkpoint blocking monoantigen; Currently, the most successful immunocheckpoint drugs are classified as PD-(L) in co-panderyIn the immunization checkpoint, in addition to PD-(L)1, there are still a lot of experiential factors that can be mined, such as LAG3, CTLA4, OX40, PVRIG, TIGIT, TIM3, ICOS, BTLA, 4-1BB, etc., at present, the main published concept verification data are CTLA4, LAG3, OX40, TIGITTigIT is the first time in 2020 ASCO to publish proof-of-concept clinical data, this is one of the great progress of this ASCO notes!is more difficult to develop in the early stages of an aggressive antibody than a blocked antibody, and the evaluation of clinical safety is more complex, so the success of an excited antibody is much more difficult! engage-1 Clinical Data Sharing (AACR Summary Number CT150)of engage-1 clinical data sharingGSK3174998 The early response rate of GSK3174998 monotherapy is still not high, and the drug combined with Paboli-Zumai 2CR, 7PR, 9SD, clinical lynx is not satisfactoryOX40 excited antibody is not optimistic at present, tavolimab, PF-04518600 early response rate of less than 5%, the reasons inside is more complex, here can not be expanded, the author will be in a different articleHowever, it should be noted that the ox40 research is far less clear than CTLA4/PD-(L)1, the future of the basic theory of the development is whether such antibodies will have a breakthrough at the rootat the same time, the AACR conference also released CTLA4/OX40 bispecific antibody ATOR-1015 first-in-human clinical data, safety, tolerance is good, please refer to the abstract CT145, no longer mentioned hereMay 14, 2020, the author inquired about the summary of tiragolumab published in 2020 ASCO, summary number 9503, Roche released the much-anticipated CITYSCAPE (GO40290, NCT03563716) key clinical data, tiragolumab joint attili single anti-attitilu adju resistance to athi-abeSingle drug can continue to significantly improve the overall response of local late metastastomy non-small cell lung cancer patients pD-L1 plus 1% by2C3IHCpharmDxDharmDxDaassay, tiragolumab combined with atlizumab monoantigen vsatlizumab anti-extended mPFS, 5.4vs.3.3.6 months, disease progression risk reduced by 43%!CITYSCAPE: Tiragolumab can help attitiletmono clinical benefits
TIGIT concept verification success, tiragolumab has undoubtedly become another high-profile immune checkpoint, especially, TIGIT mono-anti tiragolumab, based on good excellence In February and March 2020, Roche quickly launched two Phase 3 clinical sessions (NCT04256421, NCT04294810) for adaptive small cell lung and non-small cell lung cancertiragolumab antibody clinicaltrials registration information
TIGIT belongs to type I transmembrane protein, which inhibits the tumor immunoactivation of T-cell/NK cell-mediated tumor, and belongs to the immune checkpointAt present, most of these antibodies are in the early stages of clinical, evaluation of clinical data is not much, in the conduct of clinical lycinated PD-(L)1 monoantigen, Roche all-human source TIGIT monoclonal antibody tiragoab lumam progress leading, the world's first to phase 3 clinical TIGIT antibodies, there is no doubt that THE skyscraper-01/02 clinical trial progress will determine whether tiragolumab can be successfully approved for listingTIGIT single anti-domestic also has enterprises in follow-up, such as Baiji Shenzhou, Cinda Biologicalto this point, PD-(L)1 after the immune checkpoint, Baishi Meisquibo led CTLA4 antibody development, also committed to the development of a new generation of CTLA4 antibody";(Original title: 2020 ASCO Heavyweight Progress: PD-(L)1 after TIGIT single resistance or will lead the future)